Insider buying
~$997K82K sh @ $12.22
Their first buy on recordTraded Sep 5, 2025 · filed 3 days later
The CEO of Novocure paid $997K out of pocket for Novocure shares. Shares held went up 23% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
2 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Exited
Compared with the manager's Q1 2025 13F
608,672
0
−100.0%
Share count drives classification; reported value also moves with price
2
For Q2 2025
Insider buying
Their first buy on recordTraded Sep 5, 2025 · filed 3 days later
The CEO of Novocure paid $997K out of pocket for Novocure shares. Shares held went up 23% with this purchase.
Fund moves
7 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Jul 29, 2025 · filed 1 day later
The CFO of Novocure paid $116K out of pocket for Novocure shares. Shares held went up 8% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.